Dowden Nathan J
SEC CIK 1873392 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| TRDA | Entrada Therapeutics, Inc. | Pres, COO | 196.1K | — | $1.90M | 35 | 2022-03-01 | 2026-09-02 |
Most active insiders at TRDA, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | PARMAR KUSH | Dir, 10% | — | $3.65M |
| 2 | MPM BIOVENTURES 2018, L.P. | 10% | — | $3.60M |
| 3 | MPM BioVentures 2014, L.P. | 10% | — | $3.60M |
| 4 | 5AM Ventures V, L.P. | 10% | — | $3.00M |
| 5 | Baker Bros. Advisors (GP) LLC | 10% | $1.35M | — |
| 6 | WENTWORTH KORY JAMES | CFO | — | $433.6K |
| 7 | Dowden Nathan J | Pres, COO | — | $425.7K |
| 8 | Sethuraman Natarajan | Pres, Research, Develop | — | $398.8K |
| 9 | BAKER FELIX | 10% | $261.8K | — |
| 10 | Zeiher Bernhardt G | Dir | $29.3K | — |
Transactions 35
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-03 17:18 | 2026-09-02 | TRDA | Entrada Therapeutics, Inc. | Dowden Nathan J | Pres, COO | F - Tax | $7.14 | -2,528 | 196.1K | -1% | -$18.1K | |
| DT | 2026-05-04 19:24 | 2026-05-04 | TRDA | Entrada Therapeutics, Inc. | Dowden Nathan J | Pres, COO | M - OptEx | $1.74 | +15.0K | 213.6K | +8% | +$26.1K |
| DT | 2026-05-04 19:24 | 2026-05-04 | TRDA | Entrada Therapeutics, Inc. | Dowden Nathan J | Pres, COO | S - Sale+OE | $15.33 | -15.0K | 198.6K | -7% | -$230.0K |
| M | 2026-03-11 | 2026-03-09+ | TRDA | Entrada Therapeutics, Inc. | Dowden Nathan J | Pres, COO | S - Sale | $13.04 | -15.0K | 198.6K | -7% | -$195.8K |
| D | 2026-03-03 | 2026-03-01 | TRDA | Entrada Therapeutics, Inc. | Dowden Nathan J | Pres, COO | A - Grant | $0.00 | +55.8K | 234.9K | +31% | $0 |
| DM | 2026-03-03 | 2026-03-02+ | TRDA | Entrada Therapeutics, Inc. | Dowden Nathan J | Pres, COO | F - Tax | $11.73 | -21.3K | 213.6K | -9% | -$249.3K |
| 2025-09-04 | 2025-09-02 | TRDA | Entrada Therapeutics, Inc. | Dowden Nathan J | Pres, COO | F - Tax | $5.43 | -1,746 | 179.1K | -1.0% | -$9,481 | |
| D | 2025-03-04 | 2025-03-01 | TRDA | Entrada Therapeutics, Inc. | Dowden Nathan J | Pres, COO | A - Grant | $0.00 | +60.8K | 185.9K | +49% | $0 |
| D | 2025-03-04 | 2025-03-03 | TRDA | Entrada Therapeutics, Inc. | Dowden Nathan J | Pres, COO | F - Tax | $11.68 | -5,144 | 180.8K | -3% | -$60.1K |
| 2024-09-30 | 2024-09-26 | TRDA | Entrada Therapeutics, Inc. | Dowden Nathan J | Pres, COO | S - Sale | $16.00 | -847 | 125.1K | -0.7% | -$13.6K | |
| M | 2024-09-10 | 2024-09-06+ | TRDA | Entrada Therapeutics, Inc. | Dowden Nathan J | Pres, COO | S - Sale | $15.09 | -2,303 | 126.0K | -2% | -$34.8K |
| M | 2024-09-05 | 2024-09-03+ | TRDA | Entrada Therapeutics, Inc. | Dowden Nathan J | Pres, COO | F - Tax | $15.63 | -1,808 | 129.6K | -1% | -$28.3K |
| D | 2024-08-20 | 2024-08-16 | TRDA | Entrada Therapeutics, Inc. | Dowden Nathan J | Pres, COO | M - OptEx | $1.74 | +20.0K | 157.2K | +15% | +$34.8K |
| DM | 2024-08-20 | 2024-08-16 | TRDA | Entrada Therapeutics, Inc. | Dowden Nathan J | Pres, COO | S - Sale+OE | $16.27 | -27.1K | 130.1K | -17% | -$440.8K |
| 2024-03-08 | 2024-03-06 | TRDA | Entrada Therapeutics, Inc. | Dowden Nathan J | Pres, COO | S - Sale | $12.32 | -1,826 | 137.2K | -1% | -$22.5K | |
| DM | 2024-03-05 | 2024-03-04+ | TRDA | Entrada Therapeutics, Inc. | Dowden Nathan J | Pres, COO | F - Tax | $12.50 | -2,238 | 139.0K | -2% | -$28.0K |
| DM | 2024-03-05 | 2024-03-01 | TRDA | Entrada Therapeutics, Inc. | Dowden Nathan J | Pres, COO | A - Grant | $0.00 | +93.1K | 81.3K | New | $0 |
| D | 2023-09-06 | 2023-09-05 | TRDA | Entrada Therapeutics, Inc. | Dowden Nathan J | COO | F - Tax | $14.46 | -436 | 49.1K | -0.9% | -$6,305 |
| DM | 2023-09-06 | 2023-09-06 | TRDA | Entrada Therapeutics, Inc. | Dowden Nathan J | COO | S - Sale | $13.47 | -972 | 48.2K | -2% | -$13.1K |
| D | 2023-09-06 | 2023-09-01 | TRDA | Entrada Therapeutics, Inc. | Dowden Nathan J | COO | A - Grant | $0.00 | +14.2K | 49.6K | +40% | $0 |
| M | 2023-07-12 | 2023-07-10+ | TRDA | Entrada Therapeutics, Inc. | Dowden Nathan J | COO | S - Sale | $18.03 | -7,097 | 39.3K | -15% | -$127.9K |
| M | 2023-06-22 | 2023-06-20+ | TRDA | Entrada Therapeutics, Inc. | Dowden Nathan J | COO | S - Sale | $15.42 | -16.0K | 49.6K | -24% | -$246.4K |
| DA | 2023-04-19 | 2023-03-01 | TRDA | Entrada Therapeutics, Inc. | Dowden Nathan J | COO | A - Grant | $0.00 | +14.2K | 58.5K | +32% | $0 |
| D | 2023-03-03 | 2023-03-01 | TRDA | Entrada Therapeutics, Inc. | Dowden Nathan J | COO | A - Grant | $0.00 | +28.4K | 73.7K | +63% | $0 |
| D | 2023-03-03 | 2023-03-02 | TRDA | Entrada Therapeutics, Inc. | Dowden Nathan J | COO | F - Tax | $11.60 | -1,028 | 72.7K | -1% | -$11.9K |
| 2022-11-02 | 2022-10-31 | TRDA | Entrada Therapeutics, Inc. | Dowden Nathan J | COO | S - Sale | $24.05 | -2,100 | 45.3K | -4% | -$50.5K | |
| M | 2022-10-27 | 2022-10-25 | TRDA | Entrada Therapeutics, Inc. | Dowden Nathan J | COO | S - Sale | $20.77 | -9,348 | 53.7K | -15% | -$194.2K |
| M | 2022-10-24 | 2022-10-20+ | TRDA | Entrada Therapeutics, Inc. | Dowden Nathan J | COO | S - Sale | $18.66 | -6,080 | 56.7K | -10% | -$113.4K |
| M | 2022-09-28 | 2022-09-26 | TRDA | Entrada Therapeutics, Inc. | Dowden Nathan J | COO | S - Sale | $15.45 | -1,544 | 63.0K | -2% | -$23.9K |
| M | 2022-09-23 | 2022-09-21+ | TRDA | Entrada Therapeutics, Inc. | Dowden Nathan J | COO | S - Sale | $15.12 | -4,293 | 64.4K | -6% | -$64.9K |
| 2022-09-19 | 2022-09-15 | TRDA | Entrada Therapeutics, Inc. | Dowden Nathan J | COO | S - Sale | $15.01 | -100 | 68.6K | -0.1% | -$1,501 | |
| M | 2022-09-12 | 2022-09-08+ | TRDA | Entrada Therapeutics, Inc. | Dowden Nathan J | COO | S - Sale | $15.11 | -1,777 | 68.7K | -3% | -$26.8K |
| 2022-09-06 | 2022-09-01 | TRDA | Entrada Therapeutics, Inc. | Dowden Nathan J | COO | A - Grant | $0.00 | +5,632 | 70.5K | +9% | $0 | |
| 2022-06-29 | 2022-06-27 | TRDA | Entrada Therapeutics, Inc. | Dowden Nathan J | COO | S - Sale | $13.00 | -7,714 | 64.9K | -11% | -$100.3K | |
| D | 2022-03-03 | 2022-03-01 | TRDA | Entrada Therapeutics, Inc. | Dowden Nathan J | COO | A - Grant | $0.00 | +11.3K | 72.6K | +18% | $0 |
Purchase Sale Sale after option exercise All abbreviations